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Abstract: The belief that obesity is protective against osteoporosis has recently come into 
question. The latest epidemiologic and clinical studies have shown that a high level of fat mass 
might be a risk factor for osteoporosis and fragility fractures. Further, increasing evidence seems 
to indicate that different components of the metabolic syndrome, ie, hypertension, increased 
triglycerides, reduced high-density lipoprotein cholesterol, are also potential risk factors for 
the development of low bone mineral density and osteoporosis. This review considers both the 
older and more recent data in the literature in order to evaluate further the relationship between 
fat tissue and bone tissue.
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Introduction
Obesity and osteoporosis are two important global health problems with an increas-
ing prevalence and a high impact on both mortality and morbidity.1–4 Interestingly, 
during recent decades, both diseases have become a major health threat worldwide.2 
Age and female gender increase the risk of developing both obesity and osteoporosis, 
which affect millions of women.3,5–7 Age-related changes in body composition, 
metabolic factors, and hormonal levels after menopause, accompanied by a decline in 
physical activity, may all provide mechanisms for the propensity to gain weight and, 
in particular, for the increase in fat mass often characterized by replacement of lean 
mass by adipose tissue.3,4
Obesity is due to an imbalance in which energy intake exceeds energy expenditure 
over a prolonged period.2 In healthy adults, body weight is tightly regulated despite 
day-to-day variations in food intake and energy expenditure. Several environmental, 
nutritional, and hormonal factors appear to influence body weight.1–3 For instance, 
postmenopausal women often show increased body weight, likely due to a decrease in 
basal metabolism, alteration of hormonal levels, and reduced physical activity.8 More-
over, obese postmenopausal women are often affected by hypertension, dyslipidemia, 
diabetes mellitus, and cardiovascular disease, and have an increased risk of developing 
some cancers.3,9,10 Interestingly, these women have always been considered protected 
against osteoporosis.5,6,11
Osteoporosis is a metabolic bone disease characterized by excessive skeletal fragil-
ity (due to a reduction in both bone quantity and quality), leading to an increased risk 
of developing spontaneous and traumatic bone fractures.7 More than 40% of postmeno-
pausal women, on average, will suffer at least one osteoporosis fracture, often leading Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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to permanent and severe disability, nursing home placement, 
and even death.11,12 The rate of bone loss in adults reflects 
the interaction between genetic and environmental factors, 
which also influences the extent of bone acquisition during 
growth, known as peak bone mass.13
It is known that fractures in childhood have been associ-
ated with alterations in body composition, such as increased 
adiposity and bone structure, suggesting that these might 
be the earliest signs of skeletal insufficiency.14 Soon after 
menopause, the process of bone loss begins in women, 
due to increased bone resorption by osteoclasts, which 
overcomes bone formation by osteoblasts.13 Moreover, 
osteoblast function declines with aging, determining the 
imbalance between bone resorption and bone formation.15 
Traditionally, osteoporosis has been regarded as a disorder 
associated only with fracture and skeletal disability in old 
age, but recent studies demonstrate that bone mineral density 
appears to be a better long-term predictor of death than blood 
pressure or cholesterol.12,16 Further data published in recent 
decades indicate that low bone mineral density is a strong 
and independent predictor of all-cause mortality, including 
cardiovascular mortality.12,16
Body fat and lean mass are correlated with bone mineral 
density, with obesity apparently confering protection against 
bone loss after menopause.5,6,17 The pathophysiological role 
of adipose tissue in skeletal homeostasis probably lies in 
the role that several adipokines play in bone remodeling 
via their effects on either bone formation or resorption. 
Since the demonstration that bone cells express several 
specific hormone receptors, the skeleton has come to be 
  considered an endocrine target organ.18–21 Additionally, 
recent observations have shown that bone-derived factors, 
such as osteocalcin and osteopontin, may affect body weight 
control and glucose homeostasis,22–24 suggesting a possible 
role of bone tissue as an endocrine organ with the presence 
of a potential feedback mechanism between the skeleton 
and endocrine organs.25 Thus, the cross-talk between fat 
and bone likely constitutes a homoeostatic feedback system 
in which adipokines and molecules secreted by osteoblasts 
and osteoclasts represent the link of an active bone-adipose 
axis. However, the mechanism(s) by which all these events 
occur remains unclear.
Fat and bone correlation:  
evidence-based observations
In the last three decades, the association between obesity 
and osteoporosis has been actively investigated from epi-
demiological, clinical, and basic research points of view, 
and common pathophysiological links have been proposed: 
both obesity and osteoporosis are influenced by genetic and 
environmental factors, or the interaction between them; aging 
is associated with both diseases and with a high incidence 
of bone loss and bone marrow adiposity; bone remodeling 
and adiposity are both regulated via a complex interplay of 
adipokines and hormones; and adipocytes and osteoblasts 
derive from a common progenitor, ie, the mesenchymal stem 
cell,11 as shown in Figure 1.
Extensive data have shown that, in healthy pre-
menopausal and postmenopausal women, total body fat   
is positively related to bone mineral density, an important 
and measurable determinant of fracture risk,26–27 that high 
body weight (or body mass index) is correlated with high 
bone mineral   density, and that decreased body weight leads 
to bone loss.28–32 Furthermore, fat mass, the most important 
index of obesity, has been demonstrated to have a similarly 
beneficial effect, leading to an increase in bone mass,17,33 
while a beneficial effect of fat mass on bone mineral density 
is confirmed in white women but not in white men.34
Although these data indicate that obesity exerts a protec-
tive effect on bone tissue, more recent studies have described 
an opposite event. In particular, although cross-sectional and 
longitudinal studies have shown that bone mass is positively 
related to body weight and body mass index, there are con-
troversial issues as to whether lean mass or fat mass might 
be the most important determinant of bone mineral density.6 
In particular, the evidence suggests an inverse relationship 
between obesity and osteoporosis depending on how obesity 
is defined. In the studies where obesity is defined on the basis 
of body mass index or body weight, obesity appears to act as 
a protective factor against bone loss and fractures; however, 
if obesity is considered as a percentage of body fat and distri-
bution, as in the study published by Zhao et al in a Chinese 
population,11 it becomes a risk factor for osteoporosis.
In particular, there are data indicating that women with a 
high body mass index (25–29.9 kg/m2) are protected from osteo-
porosis, but there is increasing evidence conflicting with this 
observation, suggesting that obesity (body mass index . 30) 
might actually interfere with bone health.11
In accordance with the data reported by Zhao et al,11 Hsu 
et al showed that matching of Chinese subjects by body mass 
index, across 5 kg strata of body weight, revealed a negative 
relationship between fat and bone mass, and the risk of osteo-
porosis and nonspinal fractures was significantly higher for 
subjects with a higher proportion of body fat, independent of 
body weight.35 Our group has recently demonstrated that 37% 
of 395 obese adult subjects had significant skeletal changes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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In particular, this subpopulation showed a lower bone   mineral 
density at the lumbar spine than expected for both their young 
age and high body mass index.36 Further characterization 
showed that different grades of adiposity could affect skeletal 
health status differently. In fact, stratification of the popula-
tion into three different groups according to body mass index 
status, showed a slightly different bone mineral density pattern 
among the groups. Overweight subjects (body mass index 
26–29) did not show any change in skeletal health, while 
obese and severely obese subjects (body mass index . 30) 
had significant alteration in their bone mineral density levels, 
with an increased number of individuals having a lower bone 
mass than would be expected for their age and body weight.36 
Evaluation of hormonal, metabolic, and lipid profiles did not 
show significant differences between the groups, athough 
more detailed analysis seemed to show higher inflammatory 
markers and lower levels of circulating vitamin D (Migliaccio 
et al, unpublished data). Indeed, data published by Blum et al 
from a cohort of 153 premenopausal women demonstrated 
that a high amount of fat mass is negatively associated with 
bone mass.37 Thus, all these data suggest an important role 
for fat distribution as total fat mass itself. A recent study of 
907 healthy postmenopausal women by Kim et al demon-
strated that body weight was positively related to bone mineral 
density and vertebral fracture risk, whereas percentage of 
body fat and waist circumference were related to a low bone 
mineral density and to a higher risk for vertebral fractures.38
Even racial differences appear to influence fat and bone 
interaction. Castro et al reported that obesity is negatively 
associated with bone mineral density in black women, but 
not in white women,39 while Afghani and Goran reported an 
inverse correlation between subcutaneous abdominal adipose 
tissue and bone mineral density in whites, but not in blacks. 
In the same study, the authors reported an inverse association 
between visceral fat and bone mineral density in blacks, but 
not in whites.40 These conflicting results suggest a complex 
effect of fat mass on bone tissue related to sample size, ethnic-
ity, gender, study design, methods of statistical analysis, and 
population structure. Nevertheless, several lines of evidence 
from environmental and medical interventions support an 
inverse correlation between fat and bone mass, ie, physical 
exercise increases bone mass while reducing fat mass,41 
supplementation with calcium and vitamin D appears ben-
eficial for the prevention of both osteoporosis and obesity,42 
and menopause is also associated with increased fat mass, 
increased bone loss, and decreased lean mass.43 Estrogen 
replacement therapy in postmenopausal women improves 
both lean mass and bone mass, and reverses menopause-
related weight gain.44 Whereas estrogens reduce the risk of 
bone loss and obesity, other pharmacological interventions 
have been shown to increase both osteoporosis and obesity, 
such as treatment with gonadotropin-releasing hormone ago-
nists and the use of glucocorticoids.45–48 Additionally, recent 
findings have indicated that some antidiabetic drugs, which 
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Figure 1 Several cell lines deriving from a common mesenchymal stem cell. The presence of different stimuli may induce differentiation of the progenitor into one cell line 
instead of another. However, this event might underscore the presence of a certain degree of plasticity among the cell lineages.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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interfere with peroxisome proliferator-activated   receptor 
gamma (PPARγ) and thus with adipocyte differentiation, 
also appear to influence skeletal homeostasis and fracture 
risk significantly.
Thiazolidinedione and other selective PPARγ agonists, 
such as rosiglitazone and pioglitazone, play a prominent role 
in the treatment of type 2 diabetic patients. In vitro analyses 
demonstrate that various PPARγ ligands not only induce 
murine bone marrow stromal cell adipogenesis, but also 
inhibit osteogenesis,49 and in vivo studies demonstrate that 
PPARγ agonists reduce bone mineral density and increase 
fracture rates, notably distal extremity fractures in female 
type 2 diabetic patients.50
Fat and bone correlation: potential 
mechanisms of interaction
Several potential mechanisms have been proposed to explain 
the complex relationship between adipose tissue and bone 
tissue. Fat has long been viewed as a passive energy reservoir, 
but since the discovery of leptin and identification of other 
adipose tissue-derived hormones and serum mediators,51–53 fat 
has come to be considered as an active endocrine organ which 
modulates energy homeostasis. Adipose tissue also secretes 
various inflammatory cytokines, including interleukin (IL)-6 
and tumor necrosis factor-alpha,54 and altered production of 
these proinflammatory mediators is thought to have adverse 
metabolic and cardiovascular consequences. All these mol-
ecules, which include resistin, leptin, adiponectin, and IL-6, 
affect human energy homeostasis and may well be involved 
in bone metabolism, contributing to the complex relationship 
between adipose tissue and bone tissue (Figure 2).55
Fat tissue is one of the major sources of aromatase, an 
enzyme also expressed in the gonads, which synthesizes 
estrogens from androgen precursors. Estrogens are steroid 
hormones which play a pivotal role in the maintenance of 
skeletal homeostasis, protecting against osteoporosis by 
reducing bone resorption and stimulating bone formation. 
This extragonadal estrogen synthesis in fat tissue becomes 
the dominant estrogen source in postmenopausal women, due 
to the lack of ovarian function.6 Additionally, in obese post-
menopausal women, increased estrogen synthesis by adipose 
tissue has been suggested as one of the potential mechanisms 
for the protective effect of fat mass on bone.
On the other hand, studies in humans lacking aromatase 
and in estrogen receptor-α and receptor-β knockout mice 
indicate that estrogens protect against bone loss, and support 
the hypothesis that these hormones may inhibit the develop-
ment of obesity,56–61 as suggested also by the prevention of 
menopause-induced fat mass gain62–64 and reduction of the 
incidence of osteoporotic fractures by estrogen replacement 
therapy.65 In support of this hypothesis, decreased endog-
enous estrogen levels have been shown to be coupled with 
an increase in adipocyte numbers and decreased osteoblast 
counts in the bone marrow of postmenopausal women.66
As mentioned above, several adipokines are involved in 
the fat-bone interaction. Leptin suppresses appetite, increases 
energy expenditure, and regulates bone remodeling, and is the 
most important adipocyte-derived hormone.67–70 The effect of 
leptin on bone is complex, and both negative37,71 and positive 
actions72–74 on bone mineral density have been reported in 
humans. Leptin-deficient ob/ob mice and leptin receptor-
deficient db/db mice are extremely obese, with increased 
vertebral trabecular bone volume due to increased bone 
formation, despite hypogonadism and   hypercortisolism.69 
Interestingly, intracerebroventricular infusion of leptin 
in both ob/ob and wild-type mice was shown to decrease 
vertebral trabecular bone mass.69 In vivo studies indicate 
that the effect of leptin may depend on its site and mode of 
action,75–77 and it has been proposed that peripheral admin-
istration of leptin could increase bone mass by inhibiting 
bone resorption78 and increasing bone formation,52,79 while 
inhibiting bone formation through a central nervous system 
effect.69 In vitro studies also found that leptin can act directly 
on bone marrow-derived mesenchymal stem cells to enhance 
their differentiation into osteoblasts and to inhibit their dif-
ferentiation into adipocytes.79,80
Leptin,  Adiponectin, Resistin
Adipocyte
TNF-α, IL-6 Osteoblast
Osteoclast
+
Figure 2 A complex link between adipocytes and bone cell exists. Several cytokines 
are secreted by fat tissue and act on bone cells. In particular, several proinflammatory 
cytokines (eg, iL-6 and TNF-α) act as osteoclastogenic factors with a potentially 
stimulating mechanism.
Abbreviations: iL-6, interleukin-6; TNF-α, tumor necrosis factor alpha.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Takeda et al expanded these observations further, 
  demonstrating that the effects of intracerebroventricular 
leptin are mediated by the sympathetic nervous system, 
and that osteoblasts express β-adrenergic receptors via 
which it is probable that administration of β-adrenergic 
agonists decreases trabecular bone volume by inhibiting 
bone   formation.70 Noradrenaline also seems to increase bone 
resorption by promoting nuclear factor kappa-B ligand expres-
sion and inhibiting osteoblast proliferation.81–83 The effect of 
leptin on obesity is mediated via proopiomelanocortin neurons 
and neuropeptide Y.84 Leptin reduces food intake and increases 
energy expenditure by stimulating proopiomelanocortin neu-
rons to secrete α-melanocyte-stimulating hormone,85 which, 
in addition to having an effect on obesity, might contribute to 
bone resorption82 but not bone formation.70 Interestingly, type 
4 α-melanocyte-stimulating hormone receptor knockout mice 
have high bone mass due to decreased bone resorption.82
Leptin also inhibits expression of neuropeptide Y, 
a   hypothalamus-derived peptide, essential for the regula-
tion of food consumption, energy homeostasis, and bone 
remodeling.86,87 Hypothalamus-specific NPY knockout mice 
show a significant decrease in body weight, a significant 
increase in food intake, and a two-fold increase in trabecular 
bone volume compared with wild-type animals.88,89
Adiponectin is another adipocyte-derived hormone 
which has anti-inflammatory and antiatherogenic effects, 
regulating energy homeostasis and bone remodeling.90–94 In 
contrast with leptin, serum adiponectin levels are reduced in 
obese and diabetic subjects95 and increase after weight loss.92 
Human osteoblasts express adiponectin and its receptors,92 
but both negative and positive links between adiponectin 
and bone mineral density have been reported.96,97 Other in 
vivo and in vitro studies show that adiponectin increases 
bone mass by suppressing osteoclastogenesis and activating 
osteoblastogenesis,92–94 suggesting that a rise in adiponectin 
levels caused by fat reduction could have a beneficial effect 
on bone mineral density.
Thommesen et al showed that resistin may play a role in 
bone remodeling, indicating that it is expressed in mesenchy-
mal stem cells, osteoblasts, and osteoclasts in bone   marrow. 
Resistin increases osteoblast proliferation and cytokine 
release, as well as osteoclast differentiation,98 so the effect 
of resistin on bone is still unclear, and further studies are 
needed to understand its role better.
IL-6 is a pluripotent inflammatory cytokine, released from 
adipocytes, adipose tissue matrix, osteoblast, and elsewhere 
in the body.99 In particular, adipose tissue accounts for one-
third of circulating levels of IL-6. Obese subjects have high 
circulating levels of this proinflammatory cytokine,100,101 and 
genetic polymorphism of IL-6 is associated with obesity.102 
Moreover, peripheral administration of IL-6 induces hyper-
lipidemia, hyperglycemia, and insulin resistance in rodents 
and humans.103 In contrast, administration of IL-6 in the 
central nervous system increases energy expenditure and 
decreases body fat in rodents.103 IL-6 is also a well recognized 
stimulator of osteoclastogenesis and bone resorption104,105 but 
some data show that IL-6 mRNA is expressed in preosteo-
blasts and osteoblasts,106 and that IL-6 stimulates osteoblast 
proliferation and differentiation107 by controlling the pro-
duction of local factors,108 and it might play a role in bone 
formation in conditions of high bone turnover.108,109
In addition to adipocytes, adipose tissue contains various 
stromal and vascular cells, including fibroblasts, vascular 
endothelial cells, and inflammatory cells. Adipocytes were 
initially thought to be the major source of adipose-derived 
mediators, but recent studies have shown that macrophages 
infiltrate adipose tissue, and that these macrophages, along 
with other cells that reside in the stroma, also contribute to the 
production and secretion of humoral mediators, particularly 
inflammatory cytokines.54 A paracrine loop involving free 
fatty acids and inflammatory cytokines has been postulated 
to establish a vicious cycle between adipocytes and mac-
rophages, thereby propagating inflammation.110,111 Therefore, 
it is important to define interactions between adipocytes, 
osteoblasts, and stromal cells in obese subjects.
Adipocytes and osteoblasts:  
a common origin
Adipocytes and osteoblasts originate from a common 
progenitor, ie, a pluripotential mesenchymal stem cell,112 
which has an equal propensity for differentiation into adi-
pocytes or osteoblasts (or other lines) under the influence 
of several cell-derived transcription factors. This process is 
complex, suggesting significant plasticity and multifaceted 
mechanism(s) of regulation within different cell lineages, 
among which are adipocytes and osteoblasts.113,114 Several 
studies have examined the function of adipocytes in bone 
marrow. Mesenchymal stem cells isolated from marrow in 
postmenopausal osteoporotic patients express more adipose 
differentiation markers than those from subjects with normal 
bone mass.115
As mentioned earlier, adipocytes secrete endocrine and 
paracrine factors that strongly influence bone differentiation 
and remodeling. Estrogens are among these factors, explain-
ing why increased body weight in postmenopausal women is 
associated with slower rates of bone loss.113,116,117 However, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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the interaction between estrogens and fat appears to be 
  complex. Martin and Zissimos showed pronounced fatty 
infiltration in the bone marrow of rats following oophorec-
tomy, suggesting a pivotal role of estrogen in regulating 
adipocyte recruitment.118 On the other hand, the presence of 
aromatase in fat cells allows higher intramarrow conversion 
of testosterone into estrogens which, in turn, can inhibit 
bone resorption.113
The effect of estrogen on bone and adipose tissue for-
mation has long been recognized in experimental animal 
models.118,119 In humans, changes in estrogen status due to 
advancing age and menopause have been correlated with 
increased levels of IL-6 and IL-11, which are both associ-
ated with bone loss.120 It is interesting to speculate whether 
the increase in adipogenesis subsequent to menopause 
is due to a relief of repression or to an induction of the 
adipogenic phenotype, even though in vitro data suggest 
that the default “switch” might be adipogenesis, a process 
which might normally be inhibited in vivo prior to estrogen 
depletion.24
Other members of the nuclear hormone receptor family 
contribute to control of adipogenesis and osteogenesis. 
PPARγ plays a central role in initiating adipogenesis.113 
Mutations of the PPARγ gene are associated with an altered 
balance between bone and fat formation in the bone marrow. 
The nuclear hormone receptor family of transcriptional regu-
latory proteins is activated by a range of ligands, including 
steroid hormones, naturally occurring metabolites, synthetic 
chemicals, and as yet unidentified endogenous compounds 
(orphan receptors).
Thiazolidinedione and other PPARγ ligands, such as 
rosiglitazone and pioglitazone, play a prominent role in the 
treatment of type 2 diabetes. However, in vitro analyses 
demonstrate that various PPARγ ligands not only induce 
murine bone marrow stromal cell adipogenesis but also 
inhibit osteogenesis.49 In particular, PPARγ-2 is the dominant 
regulator of adipogenesis, and ligand activation of PPARγ-2 
favors differentiation of mesenchymal stem cells into adipo-
cytes rather than into osteoblasts.116 Akune et al showed that 
PPARγ insufficiency led to increased osteoblastogenesis in 
vitro and higher trabecular bone volume in vivo, confirming 
the key role of mesenchymal stem cell lineage allocation in 
the skeleton.112 Interestingly, aged mice exhibit fat infiltra-
tion into bone marrow and enhanced expression of PPARγ-2, 
along with reduced mRNA expression of bone differentiation 
factors.121 Mice with premature aging (the SAM-P/6 model) 
show nearly identical patterns of adipocyte infiltration, with 
impaired osteoblastogenesis,122 indicating that aging, or 
events that accelerate aging, result in significant bone marrow 
adiposity and a defect in osteoblastogenesis in mice.123
The Wnt signaling pathway works in a coordinated man-
ner with other transmembrane signals, including multiple 
ligands, antagonists, receptors, coreceptors, and transcriptional 
mediators, such as β-catenin.124 Specific elements of the Wnt 
signaling pathway have been found to inhibit adipogenesis125,126 
while promoting osteogenesis.127–131 Wnt inhibition of adipo-
genesis is mediated via β-catenin, which interferes with PPARγ 
transcriptional activation of downstream targets.132 Following 
exposure to transforming growth factor beta, human bone 
marrow mesenchymal stem cells increase their expression of 
various Wnt receptors and ligands.133
Members of the epidermal growth factor family, such as 
protein Pref-1, influence both adipogenesis and osteogenesis. 
In vitro analysis of human bone marrow mesenchymal stem 
cells has shown that Pref-1 overexpression blocks both adi-
pogenesis and osteogenesis. This finding is consistent with 
the hypothesis that Pref-1 maintains mesenchymal stem cells 
in a multipotent state.134
Further experimental tools, such as gene microarrays, 
are being used to document the relationship between clas-
sical steroid hormones and bone and fat formation in the 
  marrow. One study has examined the skeletal phenotype 
of mice deficient in both thyroid receptors α and β. These 
mice showed increased mRNA levels for adipocyte-specific 
genes, increased numbers of bone marrow adipocytes, and 
reduced trabecular and total bone mineral density.135 The 
inbred SAM-P/6 murine strain provides a model of acceler-
ated senescence characterized by osteopenia and increased 
fat mass in bone marrow.136 Recent studies have found 
that 1,25(OH)2 vitamin D treatment inhibits adipogenesis 
and enhances osteogenesis in SAM-P/6 mice, with a 50% 
  reduction in PPARγ mRNA and protein levels.123 Moreover, 
gene microarray analyses demonstrated coordinated induc-
tion of osteoblastogenic genes and a reduction of adipogenic 
genes after 1,25 (OH)2 vitamin D treatment, which stimulates 
not only bone formation but also bone resorption, according 
to circulating biomarkers of bone turnover.137 Overall, these 
recent findings involving classical steroid receptors support 
the inverse relationship between adipogenic and osteogenic 
differentiation in the bone marrow microenvironment. This 
is mediated, in part, by cross-talk between the pathways 
activated by steroid receptors, PPARs, and other cytokines 
and paracrine factors.
Finally, other factors, such as total caloric intake, type 
of nutrients, alcohol consumption, oxygen tension, and cel-
lular oxidation-reduction pathways influence bone marrow Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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adipogenesis despite osteoblastogenesis,24 showing that the 
bone marrow mesenchymal stem cell may consider multiple 
differentiation pathways during its lifetime and, indeed, may 
dedifferentiate and transdifferentiate in response to changes 
in the microenvironment.
Conclusion
Obesity and osteoporosis are two major global health prob-
lems with an increasing prevalence and a high impact on 
mortality and morbidity. Menopause is characterized by the 
cessation of ovarian estrogen production and is associated 
with increased bone loss, increased fat mass, and decreased 
lean mass. Age-related changes in hormone levels, in asso-
ciation with changes in body composition, metabolic fac-
tors, and decreased physical activity, probably provide the 
mechanisms for the propensity to postmenopausal gain of 
fat mass, and thus increased body weight. Estrogen synthesis 
in adipose tissue, through aromatase, becomes the dominant 
estrogen source in postmenopausal women. In particular, in 
obese postmenopausal women, increased estrogen synthesis 
by fat tissue has been suggested as one of the potential mecha-
nisms for the protective effect of fat mass on bone.
Even though there are data indicating that women with 
high body mass index are protected from osteoporosis, 
increasing evidence seems to show conflicting results regard-
ing this issue, suggesting that obesity might actually interfere 
with bone health. In particular, the relationship between 
obesity and osteoporosis depends on how obesity is defined. 
If obesity is defined on the basis of body mass index or body 
weight, it appears to protect against bone loss and fractures. 
However, if obesity is based on the percentage of body fat, 
it may be a risk factor for osteoporosis.
The existence of a cross-talk between fat and the skeleton 
suggests a homoeostatic feedback system in which adipok-
ines and bone-derived molecules form part of an active bone-
adipose axis. However, the mechanism(s) by which all these 
events occur remains unclear. Of course, further basic science 
research and epidemiological studies with large sample sizes, 
robust study design, and careful data analysis will be needed 
to show the true effect of fat mass on bone.
The relationship between fat mass and bone is confounded 
by complex genetic backgrounds and by interactions between 
metabolic factors and regulatory pathways   influencing 
both obesity and osteoporosis. Although the evidence that 
adipose tissue exerts a protective effect against bone loss is 
greater than that showing a negative association, the recent 
increasing data on this issue suggest that both obese and 
nonobese postmenopausal women should be considered at 
risk for alteration in bone mineral density and osteoporosis. 
Specific and careful characterization of skeletal metabolism 
and further studies evaluating skeleton changes may be use-
ful in obese women, because aging itself might also increase 
their risk of developing fractures later in life.
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